Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 4/20 | 0.35 |
| ▸ | DUT | P33316 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20610936 | 0.83 | CRBN (0.45) | CRBNDDB1PKMDUTALDH1A1 | |
| SCHEMBL13188311 | 0.80 | CRBN (0.50) | CRBNDDB1PKMDUTL3MBTL1 | |
| SCHEMBL10047085 | 0.78 | CRBN (0.54) | CRBNDDB1PKMDUT | |
| SCHEMBL1722581 | 0.72 | CRBN (0.52) | CRBNDDB1DUTALDH1A1 | |
| SCHEMBL22260061 | 0.72 | CRBN (0.47) | CRBNDDB1PKMHCAR1DUT | |
| SCHEMBL22779414 | 0.72 | CRBN (0.47) | CRBNDDB1PKMHCAR1DUT | |
| SCHEMBL24512475 | 0.70 | CRBN (0.44) | CRBNDDB1PKMDUTALDH1A1 | |
| SCHEMBL21524576 | 0.70 | CRBN (0.44) | CRBNDDB1PKMHCAR1DUT | |
| SCHEMBL6666896 | 0.70 | CRBN (0.44) | CRBNDDB1DUTALDH1A1LMNA | |
| SCHEMBL21803323 | 0.69 | PKM (0.47) | CRBNDDB1PKMDUTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 943 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117660383-A | Application of N-deoxyribotransferase in catalytic production of trifluridine and preparation method thereof | 杭州中美华东制药有限公司 | 2024-03-08 | — | — | CN | claimed |
| EP-3599857-A1 | HERBICIDAL MIXTURES | Bayer Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | claimed |
| WO-2018172442-A1 | HERBICIDAL MIXTURES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | claimed |
| CN-106892873-A | A kind of preparation method of 5 trifluoromethyl uracil | 内蒙古佳瑞米精细化工有限公司 | 2017-06-27 | — | — | CN | claimed |
| WO-2013020985-A1 | ACTIVE COMPOUND COMBINATIONS COMPRISING SPECIFIC TETRAMIC ACID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | WO | claimed |
| CN-1344259-A | Process for the preparation of 1, 3-oxazin-6-ones and uracils and intermediates | BASF AG (DE) | 2002-04-10 | — | — | CN | claimed |
| WO-1994017089-A2 | METHOD FOR LOCALISING AND MEASURING THE PROLIFERATION OF CANCER AND COMPOSITIONS FOR SAME | THE UNIVERSITY OF LIVERPOOL (GB) | 1994-08-04 | — | — | WO | claimed |
| EP-0351853-B1 | Method of manufacturing trifluorothymidine | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 1994-04-13 | — | — | EP | claimed |
| EP-0351853-A2 | Method of manufacturing trifluorothymidine | YUKI GOSEI KOGYO CO., LTD. (JP) | 1990-01-24 | — | — | EP | claimed |
| JP-2031686-A | — | — | None | — | — | JP | disclosed |
| JP-11246590-A | — | — | None | — | — | JP | disclosed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-0260428-A2 | Cationic surfactants and pharmaceutical compositions containing them | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-23 | — | — | EP | disclosed |
| EP-0258672-A2 | Cationic surfactants and pharmaceutical compositions containing them | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-09 | — | — | EP | disclosed |
| EP-0257400-A2 | Pharmaceutical compositions containing cationic surfactants | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-02 | — | — | EP | disclosed |
| US-3981715-A | 2,3,5-Substituted-6-trifluoromethyl-1,3-diazin-4-ones herbicides | AMERICAN CYANAMID COMPANY (US) | 1976-09-21 | — | — | US | disclosed |
| US-3954760-A | Process for producing N1 -(α-butyrolactone- and N1 (α- | GILLER SOLOMON ARONOVICH | 1976-05-04 | — | — | US | disclosed |
| JP-H00231686-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | CRBN 1816/4885DDB1 408/4885PKM 1615/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | CRBN 3187/4885DDB1 3515/4885PKM 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.